# Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

> **NCT02048709** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 22 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** GDC-0919

## Key facts

- **NCT ID:** NCT02048709
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02048709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02048709, "Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02048709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*